The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients

BMC Genetics

Elona Juozaityte²  Kastytis Smigelskas³  Jurgita Gedminaite²  Danguole Raulinaityte¹  Rasa Ugenskiene¹  Dana Myrzaliyeva²  Erika Korobeinikova² 

[1] Oncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, Eiveniu str. 2, Kaunas, LT-50009, Lithuania;Oncology Institute, Lithuanian University of Health Sciences, Eiveniu str. 2, Kaunas, LT-50009, Lithuania;Health Research Institute, Lithuanian University of Health Sciences, Betonuotoju str. 4-9, Kaunas, LT-52371, Lithuania

关键词: SNP;    Single nucleotide polymorphism;    TNFalpha;    IL10;    Prognosis;    Breast cancer;   

Others  :  1216008
DOI  :  10.1186/s12863-015-0234-8

 received in 2015-04-21, accepted in 2015-06-16,  发布年份 2015

【 摘 要 】

Background

Interleukin-10 and tumor necrosis factor α play an important role in breast carcinogenesis. Genes, encoding those two cytokines, contain single nucleotide polymorphisms, which are associated with differential levels of gene transcription. This study analyzes single nucleotide polymorphisms in interleukin 10 and tumor necrosis factor α genes and their contribution to breast cancer phenotype, lymph node status and survival in a group of young Lithuanian women with early-stage breast cancer patients.

Results

We genotyped 100 premenopausal Eastern European (Lithuanian) patients with stage I-II breast cancer, ≤50 years old at the time of diagnosis, for interleukin 10 -592A > C, −819C > T and -1082A > G and tumor necrosis factor α -308G > A single nucleotide polymorphisms in the gene promoter region. We used the polymerase chain reaction, namely a restriction fragment length polymorphism method, for a SNP analysis. All genotypes were in Hardy-Weinberg equilibrium and had the same distribution as the HapMap CEU population. Holders of IL10 -592A > C heterozygous IL10 -592 AC genotype had a higher probability of estrogen receptor positive breast cancer phenotype than homozygous variants (P = 0.017). Phased ACC haplotype of IL10 polymorphisms was associated with younger age of diagnosis (P = 0.017). Of all the tested single nucleotide polymorphisms, only TNFα -308G > A has revealed a prognostic capability for breast cancer survival. GA genotype carriers, compared to GG, showed a significant disadvantage in progression-free survival (P = 0.005, adjusted hazard ratio (HR) = 4.631, 95 % confidence interval (CI) = 1.587 – 13.512), metastasis-free survival (P = 0.010, HR = 4.708, 95 % CI = 1.445 – 15.345) and overall survival (P = 0.037, HR = 4.829, 95 % CI = 1.098 – 21.243).

Conclusions

According to our data, IL10 -1082A > G, −819 T > C, −592A > C polymorphisms and phased haplotypes have not revealed a prognostic value for breast cancer. On the contrary, the TNFα -308 polymorphism might modulate the risk and contribute to the identification of patients at a higher risk of breast cancer recurrence, metastasis and worse overall survival among young Lithuanian early-stage breast cancer patients.

【 授权许可】

   
2015 Korobeinikova et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010; 21(11):2169-2174.
• [2]Konwar R, Chaudhary P, Kumar S, Mishra D, Chattopadhyay N, Bid HK. Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. Oncol Res. 2009; 17(8):367-372.
• [3]Ramkumar HL, de Shen F, Tuo J, Braziel RM, Coupland SE, Shith JR, Chan CC. IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas. Graefes Arch Clin Exp Ophthalmol. 2012; 250(10):1541-8.
• [4]Chenjiao Y, Zili F, Haibin C, Ying L, Sheng X, Lihua H, Wei D. IL-10 promoter polymorphisms affect IL-10 production and associate with susceptibility to acute myeloid leukemia. Pharmazie. 2013; 68(3):201-6.
• [5]Howell MW, Rose-zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr. 2007;137 Suppl 1:194–199
• [6]Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RGJ, Huizinga TWJ. IL-10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA. 1998; 95:9465-9470.
• [7]Kozlowski L, Zakrzevska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003; 48:82-4.
• [8]Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, Samonigg H, Krippl P, Langsenlehner U. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat. 2010; 119(3):701-5.
• [9]Wilson AG, Di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by Ncol restriction of PCR product. Hum Mol Genet. 1992; 1:353.
• [10]Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997; 94(7):3195-9.
• [11]Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Int J Biol Markers. 2010; 25(3):126-135.
• [12]Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T et al.. Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011; 11:130. BioMed Central Full Text
• [13]Kirkpatrick A, Bidwell J, van den Brule AJ, Meijer CJ, Pawade J, Glew S. TNFalpha polymorphism frequencies in HPV-associated cervical dysplasia. Gynecol Oncol. 2004; 92(2):675-679.
• [14]Fang F, Yao L, Yu XJ, Yu L, Wu Q, Yu L. TNFalpha −308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls. Breast Cancer Res Treat. 2010; 122(1):267-71.
• [15]Kong F, Liu J, Liu Y, Song B, Wang H, Liu W. Association of interleukin-10 gene polymorphisms with breast cancer in Chinese population. J Exp Clin Cancer Res. 2010; 29:72. BioMed Central Full Text
• [16]Liu J, Song B, Wang JL, Li ZJ, Li WH, Wang ZH. Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer. World J Gastroenterol. 2011; 17(10):1362-1367.
• [17]Kaur A, Kaur A. Recurrent pregnancy loss: TNF-α and IL-10 polymorphisms. J Hum Reprod Sci. 2011; 4(2):91-4.
• [18]Hayes DF, Ethier S, Mippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat. 2006; 100:237-238.
• [19]McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006;100(2):229–235
• [20]Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68:978-989.
• [21]Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003; 73:1162-1169.
• [22]Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21(2):263-5.
• [23]Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet. 2004; 31(4):167-73.
• [24]Skerrett DL, Moore EM, Bernstein DS, Vahdat L. Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest. 2005; 23:208-214.
• [25]Balasubramanian SP, Amzy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW. Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer. 2006; 6:188. BioMed Central Full Text
• [26]Murray JL, Thompson P, Suk Young Y, Kim-anh D, Mala P et al.. Prognostic Value of Single Nucleotide Polymorphisms of Candidate Genes Associated with Inflammation in Early Stage Breast Cancer. Breast Cancer Res Treat. 2013; 138(3):917-924.
• [27]Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A. Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem. 2003; 49:1664-1667.
• [28]Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Koppel H, Wascher TC, Paulweber B, Samonigg H. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2005; 90:113-5.
• [29]Xie J, Wang S, He B, Pan Y, Li Y, Zeng Q, Jiang H, Chen J. Association of estrogen receptor alpha and interleukin10 gene polymorphisms with endometriosis in a Chinese population. Fertil Steril. 2009; 92(1):54-60.
• [30]Kidd LR, Brock GN, VanCleave TT, Benford ML, Lavender NA, Kruer TL, Wittliff JL. Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival. Cancer Causes Control. 2010; 21(10):1545-1557.
• [31]Slattery ML, Herrick JS, Torres-Mejia G, John EM, Giuliano AR, Hines LM, Stern MC, Baumgartner KB, Presson AP, Wolf RK. Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study. Carcinogenesis. 2014; 35(8):1750-1759.
• [32]Abdolrahim-Zadeh H, Hakkakian N, Asadollahi R, Gharesifard B, Sarvari J, Kamali-Sarvestani E, Talei A. Interleukin-10 Promoter Polymorphisms and Breast Cancer Risk in Iranian Women. Iranian J Immunol. 2005; 3:158-165.
• [33]Zhou C, Nitschke AM, Xiong W et al.. Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res. 2008; 10(6):R105. BioMed Central Full Text
• [34]Bertazza L, Mocellin S. The dual role of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem. 2010; 17(29):3337-3352.
• [35]Mestri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S. ChouchaneL. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer. 2001; 91(4):672-8.
• [36]Amzy IA, Balasubramanian SP, Wilson AG, Stephenson TJ, Cox A, Brown NJ, Reed MW. Role of tumour necrosis factor gene polymorphisms (−308 and −238) in breast cancer susceptibility and severity. Breast Cancer Res. 2004; 6(4):R395-400. BioMed Central Full Text